Choose Your Country or Region

Terazosin HCl Dihydrate

Name: Terazosin HCl Dihydrate
Brand: Selleck Chemicals
SKU: S2059
Rating: 5 (1 reviews)

Catalog No.S2059 Purity: 99.97%

Terazosin HCl is a selective α1-adrenoceptor antagonist, used for treatment of symptoms of an enlarged prostate (BPH).

Terazosin HCl Dihydrate Chemical Structure

CAS: 70024-40-7

Selleck's Terazosin HCl Dihydrate has been cited by 1 publication

Purity & Quality Control

Batch: S205901 DMSO] 26 mg/mL] false] Water] Insoluble] false] Ethanol] Insoluble] false Purity: 99.97%

99.97

Terazosin HCl Dihydrate Related Products

Related Targets	α-adrenergic receptor β-adrenergic receptor Beta-Adrenergic Receptor	Click to Expand
Related Products	Mirabegron Propranolol HCl Epinephrine bitartrate Phenylephrine HCl Salbutamol (Albuterol) Sulfate Zenidolol (ICI-118551) Hydrochloride Carvedilol Isoprenaline (Isoproterenol) HCl Bisoprolol fumarate Doxazosin Mesylate (−)-Norepinephrine Yohimbine HCl L755507 Sotalol HCl Nebivolol hydrochloride (R-65824) Dexmedetomidine HCl Nebivolol Salmeterol Xylazine Isoproterenol sulfate dihydrate Atipamezole Salmeterol Xinafoate Higenamine hydrochloride Terbutaline Sulfate Epinephrine HCl Carvedilol Phosphate Vilanterol Trifenate Guanabenz Acetate Indacaterol Ivabradine HCl Betaxolol Metoprolol Atenolol Salbutamol Clonidine HCl Tizanidine Acebutolol HCl Fenoterol hydrobromide Timolol Maleate Tolazoline HCl Bisoprolol Medetomidine HCl Rauwolscine hydrochloride (-)-Isoproterenol hydrochloride Maprotiline HCl Terazosin HCl Prazosin Dronedarone Indacaterol Maleate Nadolol Deoxycorticosterone acetate Betaxolol HCl Detomidine HCl Naftopidil Phentolamine Mesylate Cisatracurium Besylate	Click to Expand
Related Compound Libraries	FDA-approved Drug Library Natural Product Library Neuronal Signaling Compound Library CNS-Penetrant Compound Library Anti-alzheimer Disease Compound Library	Click to Expand

Signaling Pathway

Adrenergic Receptor Signaling Pathway

Choose Selective Adrenergic Receptor Inhibitors

Biological Activity

Description

Terazosin HCl is a selective α1-adrenoceptor antagonist, used for treatment of symptoms of an enlarged prostate (BPH).

Targets

α-adrenergic receptor ^[1]

In vitro
In vitro	Terazosin results in a significant loss of cell viability, via induction of apoptosis in a dose-dependent manner in prostate cancer cells. Terazosin suppresses prostate growth potentially via α 1-adrenoceptor-independent actions gains further support from another study documenting that Doxazosin inhibits proliferation of human vascular smooth muscle cells independently of an antagonistic effect on α1-adrenoceptor. ^[1] Terazosin blocks HERG currents in Xenopus oocytes with IC50 of 113.2 mM, while Terazosin blocks HERG channel inhibition in human HEK 293 cells with IC50 of 17.7 mM. ^[2] Terazosin or genistein treatment inhibits the growth of DU-145 cells in a dose-dependent manner, whereas has no effect on normal prostate epithelial cells. Terazosin results in the genistein-induced arrest of DU-145 cells in G2/M phase being overridden and an increase in apoptotic cells, as evidenced by procaspase-3 activation and PARP cleavage. ^[3] Terazosin induces cytotoxicity in PC-3 and human benign prostatic cells with an IC50 of more than 100 mM. ^[4]

In Vivo
In vivo	Terazosin significantly inhibits vascular endothelial growth factor induced angiogenesis in nude mice with an IC50 of 7.9 mM, showing that it has a more potent anti-angiogenic than cytotoxic effect. Terazosin also effectively inhibits vascular endothelial growth factor induced proliferation and tube formation in cultured human umbilical vein endothelial cells (IC50 9.9 and 6.8 mM, respectively). ^[4]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT04760860	Not yet recruiting	Dementia With Lewy Bodies	Qiang Zhang\|University of Iowa	October 2024	Phase 1\|Phase 2
NCT04551040	Active not recruiting	Healthy	University of Iowa\|Michael J. Fox Foundation for Parkinson''s Research	March 26 2021	Phase 1
NCT04386317	Recruiting	REM Sleep Behavior Disorder\|Pre-motor Parkinson''s Disease\|Symptomatic Parkinson Disease	Cedars-Sinai Medical Center	November 1 2020	Phase 2
NCT00449683	Completed	Hyperhidrosis	Thomas Jefferson University\|National Alliance for Research on Schizophrenia and Depression	March 2007	Phase 4
NCT00237510	Completed	Antidepressant Induced Excessive Sweating	Thomas Jefferson University	May 2005	Not Applicable
NCT02244333	Completed	Prostatic Hyperplasia	Boehringer Ingelheim	February 2004	--

References

[4] Pan SL, et al. J Urol,?003, 169(2), 724-729.

+ Expand

Chemical Information & Solubility

Molecular Weight	459.92	Formula	C₁₉H₂₅N₅O₄.HCl.2H₂O
CAS No.	70024-40-7	SDF	Download Terazosin HCl Dihydrate SDF
Smiles	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC.O.O.Cl
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 26 mg/mL ( (56.53 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):